Trevi Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRVI research report →
Range $23 – $40
Price Chart
About the company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis.
- CEO
- Jennifer L. Good
- IPO
- 2019
- Employees
- 34
- HQ
- New Haven, CT, US
Get TickerSpark's AI analysis on TRVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.90B
- P/E
- -35.38
- PEG
- 3.83
- P/S
- 0.00
- P/B
- 7.24
- EV/EBITDA
- -31.78
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -24.81%
- ROIC
- -23.09%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-49,328,000
- Net Income
- $-42,759,000+10.8%
- EPS
- $-0.29+38.3%
- OCF Growth
- -10.0%
- FCF Growth
- -10.0%
- 52W High
- $20.22
- 52W Low
- $9.82
- 50D MA
- $13.78
- 200D MA
- $14.57
- Beta
- 0.98
- RSI (14)
- 50
- Avg Volume
- 1.98M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Trevi said it remains on track across its cough programs, with cash runway into 2030, continued progress in IPF chronic cough, and clearer FDA alignment on a new non-IPF ILD study.· November 9, 2026
- OCEAN-1 and OCEAN-2 in IPF-related chronic cough are underway, with the company saying enrollment and site activation are progressing and timelines remain unchanged.
- Trevi reached alignment with the FDA on a Phase II dose-ranging study in non-IPF ILD cough, planned for 120 patients and expected to start in Q1 2027.
- The RCC LAKE study will undergo a sample size reestimation at 50 patients/50% completion; management said the interim only informs powering, not the final readout strategy.
- Cash was $299 million at quarter-end, and management said that supports runway into 2030, funding key clinical milestones but not commercial launch or any Phase III RCC or non-IPF ILD studies.
- Management said recent competitive failures leave Trevi as the only active player in its targeted chronic cough indications, which it views as a strategic advantage.
Trevi ended Q3 2026 with approximately $299 million in cash, cash equivalents and marketable securities. Management said cash runway extends into 2030. The company did not provide revenue, EPS, or gross margin figures on the call. Forward guidance included: OCEAN-2 12-week data in 2H 2027, OCEAN-1 24-week efficacy/52-week safety data in 1H 2028, the non-IPF ILD Phase II study to initiate in Q1 2027 with top-line data in 1H 2028, and RCC LAKE SSRE results in early Q1 with full trial results still expected in 2H 2027. Management also said the current cash balance fully funds the ongoing Phase IIb LAKE trial, as well as non-IPF ILD Phase II top-line data and pre-commercial work, but not a commercial launch or any Phase III trials in RCC or non-IPF ILD.
Jennifer Good framed 2026 as an execution year, emphasizing site activation, enrollment, and regulatory coordination across all programs. She highlighted FDA alignment on non-IPF ILD as a key step, and described the plan as a stepwise path to becoming a leader in chronic cough. Her tone was confident and upbeat, especially around the absence of active competitors in RCC and the potential for Haduvio across multiple cough indications.
David Hastings focused on balance sheet strength and capital allocation. He said Trevi ended the third quarter with about $299 million in cash, cash equivalents and marketable securities and that the runway extends into 2030, enough to fund the clinical program through key inflection points including potential FDA approval in IPF-related chronic cough. He added that current resources fully fund the LAKE RCC trial and cover the upcoming non-IPF ILD Phase II study through top-line data, but do not include costs for a commercial launch or any Phase III RCC or non-IPF ILD trial.
Analysts pressed on the ILD FDA meeting, and management said it was very positive, with no unusual requirements beyond showing the right doses in a broader, more heterogeneous non-IPF ILD population. On RCC, questions focused on the SSRE, enrollment pace, and whether the result could alter program strategy; management said the interim is designed only to confirm powering, not to provide a read on efficacy drivers, and that it will likely not change the broader RCC plan until the full data are available. Analysts also asked about market size, commercialization, and patent protection, and management pointed to an estimated severe RCC market of around 1 million patients, a focus on pulmonologists, and a new patent that extends non-IPF ILD dosing protection to 2041.
The company believes it now has regulatory alignment in non-IPF ILD, with a clear Phase II dose-ranging path and a plausible sNDA-based route to a single Phase III study. Management also emphasized that no active competitors remain in RCC or the other targeted chronic cough indications, which it views as strengthening the opportunity for Haduvio if efficacy holds. Cash runway into 2030 reduces near-term financing pressure and supports multiple data readouts.
Trevi is still early in the execution phase, so the investment case depends on successful enrollment, clean dose selection, and later-stage efficacy confirmation across multiple programs. The RCC trial’s SSRE introduces uncertainty, and management acknowledged variability, placebo effects, and the heterogeneity of chronic cough as core development risks. The company also said current cash does not cover commercialization or any Phase III program in RCC or non-IPF ILD, so additional funding would be needed for those steps.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.0%
- Shares Outstanding
- 142.56M
- Float Shares
- 118.38M
of shares held by institutions
226 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 13.63M | ▲ 1.07M |
| Nea Management Company, LLC | 13.22M | 0 |
| Blackrock, Inc. | 12.29M | ▲ 1.13M |
| Frazier Life Sciences Management, L.P. | 9.94M | ▼ 100 |
| Vanguard Group Inc | 6.43M | ▲ 607.67K |
| Vanguard Capital Management LLC | 6.11M | ▲ 581.94K |
| Wellington Management Group Llp | 5.68M | ▲ 495.50K |
| Vivo Capital, LLC | 4.23M | ▼ 864.99K |
| Woodline Partners LP | 4.08M | ▲ 3.08M |
| Assenagon Asset Management S.A. | 3.53M | ▲ 2.00M |
| State Street Corp | 3.27M | ▲ 245.08K |
| Marshall Wace, Llp | 3.15M | ▲ 476.65K |
Held by 232 ETFs
Biggest fund positions in TRVI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Heffernan Michael Thomas | other | 21,052 |
| Sep 15, 26 | Heffernan Michael Thomas | other | 18,421 |
| Sep 15, 26 | Heffernan Michael Thomas | sell | 20,952 |
| Sep 15, 26 | Heffernan Michael Thomas | sell | 100 |
| Sep 15, 26 | Heffernan Michael Thomas | other | 18,421 |
| Sep 15, 26 | Heffernan Michael Thomas | other | 21,052 |
| Jun 3, 26 | Mathers Edward T | other | 35,000 |
| Jun 3, 26 | Colangelo Dominick | other | 35,000 |
| Jun 3, 26 | Meeker David P | other | 35,000 |
| Jun 3, 26 | VANLENT ANNE | other | 35,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRVI coverage
Recent articles, reports, and earnings notes.
No research on TRVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRVI report →Trevi Therapeutics: The P2X3 Collapse Leaves Haduvio Standing Alone In Chronic Cough
seekingalpha.com · Nov 19
Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 9
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
globenewswire.com · Nov 2
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
globenewswire.com · Oct 27
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
globenewswire.com · Oct 13
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.